Optiscan Imaging (OIL.AX) Aktie Kurs
Optiscan Imaging Kurs
Omsætningen i Optiscan Imaging er faldet med 12,5 % om året de seneste 19 år til 448.769,00 AUD. Optiscan Imagings nettoavance ligger på -1.556,7 %, ned fra -417,9 % for flere år siden.
Optiscan Imaging aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Optiscan Imaging aktie og aktieanalyse
Hyppigt stillede spørgsmål om Optiscan Imaging-aktien
The business model of Optiscan Imaging Ltd focuses on developing and commercializing advanced medical imaging technologies. The company specializes in the design and manufacture of confocal laser endomicroscopes, which are used in various medical applications. Optiscan Imaging aims to improve the diagnosis and treatment of diseases through their innovative imaging solutions. By leveraging their expertise in advanced imaging technologies, the company aims to provide healthcare professionals with high-quality and real-time cellular imaging during medical procedures. Optiscan Imaging Ltd's business model is centered around offering cutting-edge medical imaging technologies that deliver precise and detailed cellular imaging for improved patient outcomes.
Optiscan Imaging Ltd is primarily active in the medical technology and healthcare industries.
The main competitors of Optiscan Imaging Ltd in the market include companies such as Carl Zeiss Meditec AG, NIDEK CO., LTD., and Topcon Corporation.
Optiscan Imaging Ltd is a renowned company specializing in medical imaging technologies. Established in [year], Optiscan has achieved significant milestones in the field of diagnostic imaging. The company is known for its innovative optical imaging systems, such as confocal microscopy, which provide high-resolution cellular images for diagnostic purposes. Optiscan Imaging Ltd has a rich history of research and development, consistently striving to push the boundaries of medical imaging. With its advanced imaging solutions, Optiscan continues to contribute to the progression of healthcare.
Optiscan Imaging Ltd has achieved several significant milestones. The company successfully developed and patented a revolutionary confocal endomicroscopy technology, which enables real-time, high-resolution imaging of living tissue. Optiscan Imaging Ltd also received clearance from the U.S. Food and Drug Administration (FDA) for its confocal endomicroscopy system, facilitating its entry into the American market. Furthermore, the company collaborated with renowned medical institutions and researchers worldwide to conduct clinical studies and validate the efficacy of its imaging technology. Optiscan Imaging Ltd's relentless dedication to innovation and research has positioned it as a leader in the field of real-time tissue imaging.
Optiscan Imaging Ltd is primarily present in Australia.
Optiscan Imaging Ltd is a company known for its strong commitment to innovation and excellence in medical imaging. With a vision to improve patient outcomes, Optiscan prides itself on providing cutting-edge solutions for real-time cellular imaging. The company's corporate philosophy revolves around leveraging advanced technology to enhance diagnostic accuracy and enhance the effectiveness of medical procedures. Optiscan Imaging Ltd values integrity, collaboration, and a customer-centric approach, ensuring that their products and services meet the evolving needs of the medical community. By prioritizing research and development, Optiscan aims to revolutionize the field of medical imaging, while maintaining a steadfast dedication to quality and patient care.
Omregnet til den aktuelle valutakurs handles Optiscan Imaging-aktien til 0,10 EUR (0,16 AUD).
Optiscan Imaging-aktien (OIL.AX) er noteret på 1 børser, herunder: ASX (OIL.AX).
Optiscan Imaging Ltd is a leading provider of high-quality microscope systems and components for scientific research, medical diagnostics, and industrial testing and quality assurance. The company was founded in Melbourne, Australia in 1994 and has since expanded its operations worldwide. Today, Optiscan Imaging is a global company that delivers innovative technologies and products to meet the needs of its customers in various industries.
-omsætningen for Optiscan Imaging er 448.769,00 AUD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
-overskuddet for Optiscan Imaging er -6,99 Mio. AUD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Optiscan Imaging er i øjeblikket -23,17. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Optiscan Imaging-aktien.
Pris-til-salgs-forholdet (P/S) for Optiscan Imaging er i øjeblikket 360,65. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Optiscan Imaging-aktien.
AlleAktien-kvalitetsscore for Optiscan Imaging er 2/10.
ISIN for Optiscan Imaging er AU000000OIL4. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Optiscan Imaging er 932111. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Optiscan Imaging er OIL.AX. Tickersymbolet bruges til at handle Optiscan Imaging-aktier på børsen.
Optiscan Imaging aktie
Optiscan Imaging Peer Group
Optiscan Imaging Ticker
Optiscan Imaging FIGI
Alle fundamentale data om Optiscan Imaging i deep dive
Vores aktieanalyse af Optiscan Imaging-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Optiscan Imaging. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: